Welcome to our dedicated page for DOSEOLOGY SCIENCES news (Ticker: DOSEF), a resource for investors and traders seeking the latest updates and insights on DOSEOLOGY SCIENCES stock.
Doseology Sciences Inc. develops consumer products around precision-controlled oral stimulant pouch technologies. News about Doseology Sciences centers on its non-nicotine, caffeine-based Feed That Brain Energy Pouches, direct-to-consumer distribution in the United States, pilot production, brand development, and the use of oral pouch formats for controlled stimulant delivery.
Company updates also cover OTCQB trading under DOSEF, capital-markets communications, governance changes, and regulatory strategy for oral pouch products, including formulation, data generation, PMTA preparation, and post-market compliance themes tied to regulated consumer stimulant categories.
Doseology (OTCQB: DOSEF) arranged a non-brokered private placement to raise up to $2.0M by issuing up to 3,225,806 Units at $0.62 per Unit. Each Unit includes one share and one two-year warrant exercisable at $1.00, subject to acceleration.
The company said net proceeds will fund commercialization of its oral stimulant pouch platform: production equipment, pilot manufacturing facility, initial runs, inventory, marketing, distribution expansion and general working capital. Closing is subject to CSE approval and securities hold/resale restrictions.
Doseology (OTCQB: DOSEF) commenced trading on the OTCQB Venture Market on March 11, 2026, expanding U.S. investor access and aligning the company with higher reporting and governance standards. The company appointed Larry Latowsky as Executive Chairman and disclosed pre-funded warrant issuances tied to its Feed That Brain acquisition.
Doseology issued 75,000 pre-funded warrants at a deemed $1.00 price, with additional $75,000 issuances due at the one-year and 18-month anniversaries; the four-month hold on the initial warrants expires July 11, 2026.
Doseology (OTCQB: DOSEF) launched Feed That Brain® Energy Pouches in a U.S. direct-to-consumer pilot on March 4, 2026. The nicotine-free, caffeine-based oral pouches are available exclusively at feedthatbrain.com and Amazon.com, designed for portion-controlled, discreet stimulation without sugar, smoke, or liquid.
The pilot will evaluate consumer adoption, usage frequency, and repeat purchase behaviour to validate oral pouch delivery as a scalable stimulant platform. The company also granted 140,000 RSUs (vesting monthly over 36 months) and 210,000 PSUs tied to performance milestones.
Doseology (PINK:DOSEF; CSE:MOOD) appointed Larry Latowsky as director and Executive Chairman, effective February 18, 2026. The company granted 4,000 RSUs (36-month monthly vesting) and 6,000 PSUs tied to performance milestones. Doseology positions itself to scale precision oral stimulant delivery with strengthened governance and capital-markets expertise.
Latowsky brings pharmacy retail, manufacturing, and deal experience, including leadership roles at Katz Group and involvement in a ~C$3 billion transaction with McKesson.
Doseology (PINK: DOSEF) has begun a pilot production run of non‑nicotine, caffeine‑based energy pouches under its wholly owned Feed That Brain brand. The pilot is a limited direct‑to‑consumer initiative launching in the coming weeks and is exploratory, not a commercial roll‑out.
The pouch format emphasizes portioned, non‑liquid caffeine delivery focused on consistency, predictability, and user control. Doseology positions the pilot to gather product testing, consumer feedback, and operational learnings to inform future formulation, delivery design, and commercialization decisions.
Doseology (DOSED) filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+ to consolidate disclosure on business, strategy, risk factors, governance, and capital structure. The AIF aims to improve investor transparency and accessibility by combining information previously spread across multiple documents. The filing does not announce any financing or offering and is process-driven to maintain disclosure readiness and potential short-form prospectus eligibility under NI 44-101.
Doseology (ticker: DOSED) announced a strategic partnership with McKinney Regulatory Science Advisors to advance regulatory execution and commercial readiness for Doseology's oral pouch product portfolio. McKinney will advise on formulation strategy, data generation, Pre-market Tobacco Product Application (PMTA) preparation, labeling, and post-market compliance to support nicotine and nicotine-analogue pouch formats. The engagement aims to accelerate FDA pathway navigation, align R&D and manufacturing validation with regulatory expectations, strengthen IP and dose-consistency controls, and establish post-market surveillance and adverse-event reporting frameworks.
The collaboration is positioned to move Doseology from development toward regulated-market readiness while emphasizing consumer safety and regulatory-aligned product design.
Doseology (PINK: DOSEF) launched an Investor Communications Initiative on December 1, 2025 to strengthen disclosure, expand investor engagement, and support its commercial and capital‑markets strategy. The program includes a 3‑month engagement with Guerilla Capital (Dec 1, 2025–Feb 28, 2026) for $30,000 CAD, and a digital media agreement with Maynard Communications (commencing Dec 1, 2025; term listed to May 31, 2026) for $200,000 CAD. The company said the initiative will align reporting with governance standards, broaden retail and institutional visibility, and support commercialization of its oral stimulant platform. Regulatory disclosures state both firms or their principals currently hold Doseology securities and engagements are not at arm’s length; compensation is not tied to stock performance.
Doseology (PINK: DOSEF) announced that its wholly owned U.S. subsidiary, Doseology USA Inc., executed a confidential manufacturing agreement with a leading North American production partner on November 13, 2025. The partner operates an FDA-registered, GMP-certified, ISO 9001:2015 facility and offers end-to-end manufacturing for oral stimulant pouches including formulation, ingredient sourcing, pouch filling, packaging, and logistics. Doseology says the agreement provides scalable production from pilot runs to high-volume commercial output and establishes the operational and regulatory foundation to move from R&D toward market readiness in North America.
Summary not available.